Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Head-to-Head trial tests new hope for Tough-to-Treat lymphoma

NCT ID NCT06082102

Summary

This study compares two different drug combinations for people whose marginal zone lymphoma has returned or hasn't responded to previous treatment. Researchers will test whether orelabrutinib plus rituximab works better than lenalidomide plus rituximab at keeping the cancer from progressing. The trial involves 324 adults who have already tried at least one prior treatment containing an anti-CD20 antibody.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Beijing Tiantan Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100070, China

    Contact

  • Beijing Tongren Hospital, Capital Medical University

    RECRUITING

    Beijing, Beijing Municipality, 100730, China

    Contact

  • Fudan University Shanghai Cancer Center

    RECRUITING

    Shanghai, Shanghai Municipality, 200040, China

    Contact

  • Guangdong Provincial Hospital of Chinese Medicine

    RECRUITING

    Guangzhou, Guangdong, 510120, China

    Contact

  • Henan Cancer Hospital

    RECRUITING

    Zhengzhou, Henan, 450003, China

    Contact

  • Henan Provincial Peoples Hospital

    RECRUITING

    Zhengzhou, Henan, 450003, China

    Contact

  • Hunan Cancer Hospital

    NOT_YET_RECRUITING

    Changsha, Hunan, 410000, China

    Contact

  • Jiangxi Cancer Hospital

    RECRUITING

    Nanchang, Jiangxi, 330029, China

    Contact

  • Sun Yat-sen University Cancer Center

    RECRUITING

    Guangzhou, Guangdong, 510055, China

    Contact

  • The Affiliated Hospital Of Qingdao University

    NOT_YET_RECRUITING

    Qingdao, Shandong, 266000, China

    Contact

  • The First Affiliated Hospital of Bengbu Medical College

    RECRUITING

    Bengbu, Auhui, 233000, China

    Contact

  • The First Affiliated Hospital of Nanchang University

    RECRUITING

    Nanchang, Jiangxi, 330006, China

    Contact

  • The First Affiliated Hospital of Zhejiang University School of Medicine

    RECRUITING

    Hangzhou, Zhejiang, 310003, China

    Contact

  • The Second Affiliated Hospital of Xi'an Jiaotong University(Xibei Hospital)

    RECRUITING

    Xi’an, Shanxi, 710004, China

    Contact

  • The Second Hospital of Dalian Medical University

    RECRUITING

    Dalian, Liaoning, 116023, China

    Contact

  • The first Hospital of China Medical University

    RECRUITING

    Shenyang, Liaoning, 110002, China

    Contact

  • Union Hospital Tongji Medical College Huazhong University of Science and Technology

    RECRUITING

    Wuhan, Hubei, 430000, China

    Contact

  • West China Hospital, Sichuan University

    NOT_YET_RECRUITING

    Chengdu, Sichuan, 610041, China

    Contact

  • Yantai Yuhuangding Hospital

    RECRUITING

    Yantai, Shandong, 264099, China

    Contact

Conditions

Explore the condition pages connected to this study.